Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
There is a need for more effective and better-tolerated hepatitis B vaccines for low
responder high-risk populations including patients with renal impairment and/or diabetes
mellitus and those aged over 40 years. Several approaches are available to enhance the
potency of hepatitis B virus vaccines including use of the more highly immunogenic antigens,
replacing alum with potentially more effective adjuvants, and increasing the dose of vaccine
antigen. A combination of these strategies is being tested in this study to identify the most
promising candidate approaches to take forward into advanced clinical development